Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | SRC | P12931 | 7/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218433 | 0.90 | KDM4E (0.51) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL23170359 | 0.87 | ABL1 (0.54) | ABL1SRC | |
| SCHEMBL2872235 | 0.85 | KDM4E (0.46) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL5218804 | 0.85 | KDM4E (0.57) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL24201478 | 0.83 | KDM4E (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL19592610 | 0.83 | ABL1 (0.43) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL14802296 | 0.82 | ALOX15 (0.59) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL833789 | 0.82 | KDM4E (0.48) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL1313379 | 0.82 | KDM4E (0.48) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL15223892 | 0.81 | ABL1 (0.45) | ALDH1A1HPGDGLAABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-10039755-B2 | 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2018-08-07 | — | — | US | disclosed |
| US-20180161316-A1 | 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-9833449-B2 | 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170119750-A1 | 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| US-9518054-B2 | 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| EP-2877467-B1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | GLAXO GROUP LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-20160009716-A1 | 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9127003-B2 | 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | Glaxo Group Limited a corporation | 2015-06-25 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2007047207-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039755-B2 | 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors | PADI1, PADI4, PADI2 | RAB9A 3041/4885NPC1 2637/4885KDM4E 1362/4885 |
| US-20160009716-A1 | 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | RAB9A 2457/4885NPC1 2801/4885KDM4E 1772/4885 |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | RAB9A 3493/4885NPC1 3726/4885KDM4E 2621/4885 |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | RAB9A 3232/4885NPC1 2757/4885KDM4E 1448/4885 |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | RAB9A 3493/4885NPC1 3726/4885KDM4E 2621/4885 |
| US-20180161316-A1 | 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | RAB9A 3064/4885NPC1 2627/4885KDM4E 1357/4885 |
| US-20170119750-A1 | 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | RAB9A 3056/4885NPC1 2560/4885KDM4E 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.